MedX Health and Health Partners Announce Agreement to Launch MedX’s Teledermatology Screening Platform in the United Kingdom

MedX Health Corp. ("MedX" or the "Company") (TSXV: MDX), a global leader in teledermatology, is pleased to announce a Memorandum of Understanding (“MOU”) and the launch of a new commercialization pilot project with Health Partners (OH) Limited, a well-respected, privately-owned corporate health, treatment and primary care services company in the United Kingdom. Serving a broad client base comprising corporates, government agencies, insurers, health trusts, pension funds and individuals, Health Partners (“HP”) employs 700+ people with telehealth, mobile and on-site operations across the UK and the Republic of Ireland.

The pilot will span three to six months and involve an estimated 600 patients across two of HP’s sites. Upon the successful completion of the pilot, the MedX DermSecure® Screening Platform will be made available to Health Partners' two million-plus patients. The agreement is the latest initiative in MedX’s global commercialization strategy and follows pilots recently launched across the Europe and Middle East region.

"Health Partners’ Clinical Team constantly strives to identify leading technological innovations that offer the highest level of support to our two million-plus patients," said Health Partners Managing Director Andrew Noble. “MedX's leading skin assessment technology allows dermatologists to not only make more accurate diagnoses of pigmented lesions and moles, but to do that remotely and quickly. We are very proud to be partnering with MedX Health to bring this innovative and life-changing service to our clients.”

In addition to expanding its DermSecure® Screening Platform network globally, MedX has focused on building a presence in multiple market verticals such as pharmacies, medical clinics, building hubs, medical scanning clinics, mobile and remote medical practices, as well as esthetics and skincare clinics. The partnership with Health Partners represents MedX’s expansion into a new vertical; occupational health and wellbeing services.

MedX Managing Director, Europe, Middle East and Africa (EMEA), Naman Demaghlatrous, added, "MedX is pleased to have established a presence in the strategic occupational health vertical. Health Partners brings our technology to a population of more than two million workers across the United Kingdom, thus expanding our footprint in the EMEA region considerably. We continue to execute on our strategy to identify strategic partnerships in the region that will allow us to grow our business and save lives simultaneously.”

Health Partners will pilot MedX’s high-definition image-capture technology, SIAscopy®, and its secure, cloud-based patient management system, DermSecure®, which transmits and stores patient data throughout the assessment process. MedX's SIAscopy® is the only technology available that captures five high-resolution images of suspicious moles, lesions and skin conditions, including four spectrophotometric images taken 2mm below the skin's surface. This technology provides detailed patient scans, which a certified dermatologist can virtually assess within 72 hours.

"We are honoured to be working with Health Partners on this most important initiative. According to Health & Safety Executive-commissioned research, there are more than 3,000 cases of skin cancer annually in the construction industry alone. We are delighted to be entering the occupational health services market with a leader in the industry," stated Mike Druhan, MedX President, Dermatology Services.

About Health Partners (OH) Ltd.

Health Partners, headquartered in Uckfield, East Sussex, United Kingdom, is a leading health and wellbeing company, providing a full range of corporate health, treatment and primary care services to corporates, government, insurers, health trusts, pension funds and families. We combine expert advice and clinical services with smart systems to deliver impact-driven health programmes, tailored to improve people’s wellbeing and performance.

Health Partners is founded on patient privacy and holds a significant number of accreditations, certifications and memberships, including ISO27001, CQC, SEQOHS and ISO9001. Health Partners offers its services across the United Kingdom and the Republic of Ireland, reaching two million plus people in organisations across several industries. For more information, visit www.healthpartners.uk.com.

About MedX Health Corp.

MedX, headquartered in Ontario, Canada, is a leading medical device and software company focused on skin health with its SIAscopy® on DermSecure® telemedicine platform, utilizing its SIAscopy® technology. SIAscopy® is also imbedded in its products SIAMETRICS®, SIMSYS®, and MoleMate®, which MedX manufactures in its ISO 13485 certified facility. SIAMETRICS®, SIMSYS®, and MoleMate® include hand-held devices that use patented technology utilizing light and its remittance to view suspicious moles and lesions up to 2mm beneath in a pain-free, non-invasive manner. Its patented software then creates real-time images for physicians and dermatologists to evaluate all types of moles or lesions within seconds. These products are cleared by Health Canada, the U.S. Food and Drug Administration, the Therapeutic Goods Administration and Conformité Européenne for use in Canada, the U.S., Australia, New Zealand, the European Union, Brazil and Turkey. For more information, visit www.medxhealth.com.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

This Media Release may contain forward-looking statements, which reflect the Company's current expectations regarding future events. The forward-looking statements involve risks and uncertainties.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220302005737/en/

Bill Mitoulas, Investor Relations
MedX Health Corp.
[email protected]
+1-416-479-9547